The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1

Yusuke Niina, Nao Fujimori, Taichi Nakamura, Hisato Igarashi, Takamasa Oono, Kazuhiko Nakamura, Masaki Kato, Robert T. Jensen, Tetsuhide Ito, Ryoichi Takayanagi

Research output: Contribution to journalReview article

21 Citations (Scopus)

Abstract

Multiple endocrine neoplasia type 1 (MEN1) is an inherited autosomal dominant disease presenting with pancreatic neuroendocrine tumors (pNETs), parathyroid tumors, or pituitary tumors. Using the PubMed database, we reviewed the literature on information regarding the proper diagnosis and treatment of MEN1-associated pNET. Many cases of MEN1-associated pNET are functioning pNETs. Gastrinomas and insulinomas tend to occur frequently in the duodenum and pancreas, respectively. In addition to diagnostic imaging, the selective arterial secretagogue injection test (SASI test) is useful for localizing functioning pNET. The standard treatment is surgical resection. However, in the case of a functioning pNET, the tumor should first be accurately located using the SASI test before an appropriate surgical method is selected. In cases of a MEN1-associated non-functioning pNET that exceeds 2 cm in diameter, the incidence of distant metastasis is significantly increased, and surgery is recommended. In cases of unresectable pNET, a somatostatin analog has been shown to demonstrate antitumor effects and is considered to be a promising treatment. In addition, molecular-targeted drugs have recently been found to be effective in phase III clinical trials.

Original languageEnglish
Pages (from-to)287-294
Number of pages8
JournalGut and Liver
Volume6
Issue number3
DOIs
Publication statusPublished - Jul 1 2012

Fingerprint

Multiple Endocrine Neoplasia Type 1
Neuroendocrine Tumors
Gastrinoma
Phase III Clinical Trials
Insulinoma
Injections
Pituitary Neoplasms
Diagnostic Imaging
Somatostatin
Duodenum
PubMed
Pancreas
Neoplasms
Therapeutics
Databases
Neoplasm Metastasis
Incidence

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cite this

The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. / Niina, Yusuke; Fujimori, Nao; Nakamura, Taichi; Igarashi, Hisato; Oono, Takamasa; Nakamura, Kazuhiko; Kato, Masaki; Jensen, Robert T.; Ito, Tetsuhide; Takayanagi, Ryoichi.

In: Gut and Liver, Vol. 6, No. 3, 01.07.2012, p. 287-294.

Research output: Contribution to journalReview article

Niina, Yusuke ; Fujimori, Nao ; Nakamura, Taichi ; Igarashi, Hisato ; Oono, Takamasa ; Nakamura, Kazuhiko ; Kato, Masaki ; Jensen, Robert T. ; Ito, Tetsuhide ; Takayanagi, Ryoichi. / The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1. In: Gut and Liver. 2012 ; Vol. 6, No. 3. pp. 287-294.
@article{036915a99cd44d0e8ed8a358630fff49,
title = "The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1",
abstract = "Multiple endocrine neoplasia type 1 (MEN1) is an inherited autosomal dominant disease presenting with pancreatic neuroendocrine tumors (pNETs), parathyroid tumors, or pituitary tumors. Using the PubMed database, we reviewed the literature on information regarding the proper diagnosis and treatment of MEN1-associated pNET. Many cases of MEN1-associated pNET are functioning pNETs. Gastrinomas and insulinomas tend to occur frequently in the duodenum and pancreas, respectively. In addition to diagnostic imaging, the selective arterial secretagogue injection test (SASI test) is useful for localizing functioning pNET. The standard treatment is surgical resection. However, in the case of a functioning pNET, the tumor should first be accurately located using the SASI test before an appropriate surgical method is selected. In cases of a MEN1-associated non-functioning pNET that exceeds 2 cm in diameter, the incidence of distant metastasis is significantly increased, and surgery is recommended. In cases of unresectable pNET, a somatostatin analog has been shown to demonstrate antitumor effects and is considered to be a promising treatment. In addition, molecular-targeted drugs have recently been found to be effective in phase III clinical trials.",
author = "Yusuke Niina and Nao Fujimori and Taichi Nakamura and Hisato Igarashi and Takamasa Oono and Kazuhiko Nakamura and Masaki Kato and Jensen, {Robert T.} and Tetsuhide Ito and Ryoichi Takayanagi",
year = "2012",
month = "7",
day = "1",
doi = "10.5009/gnl.2012.6.3.287",
language = "English",
volume = "6",
pages = "287--294",
journal = "Gut and Liver",
issn = "1976-2283",
publisher = "Joe Bok Chung",
number = "3",

}

TY - JOUR

T1 - The current strategy for managing pancreatic neuroendocrine tumors in multiple endocrine neoplasia type 1

AU - Niina, Yusuke

AU - Fujimori, Nao

AU - Nakamura, Taichi

AU - Igarashi, Hisato

AU - Oono, Takamasa

AU - Nakamura, Kazuhiko

AU - Kato, Masaki

AU - Jensen, Robert T.

AU - Ito, Tetsuhide

AU - Takayanagi, Ryoichi

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Multiple endocrine neoplasia type 1 (MEN1) is an inherited autosomal dominant disease presenting with pancreatic neuroendocrine tumors (pNETs), parathyroid tumors, or pituitary tumors. Using the PubMed database, we reviewed the literature on information regarding the proper diagnosis and treatment of MEN1-associated pNET. Many cases of MEN1-associated pNET are functioning pNETs. Gastrinomas and insulinomas tend to occur frequently in the duodenum and pancreas, respectively. In addition to diagnostic imaging, the selective arterial secretagogue injection test (SASI test) is useful for localizing functioning pNET. The standard treatment is surgical resection. However, in the case of a functioning pNET, the tumor should first be accurately located using the SASI test before an appropriate surgical method is selected. In cases of a MEN1-associated non-functioning pNET that exceeds 2 cm in diameter, the incidence of distant metastasis is significantly increased, and surgery is recommended. In cases of unresectable pNET, a somatostatin analog has been shown to demonstrate antitumor effects and is considered to be a promising treatment. In addition, molecular-targeted drugs have recently been found to be effective in phase III clinical trials.

AB - Multiple endocrine neoplasia type 1 (MEN1) is an inherited autosomal dominant disease presenting with pancreatic neuroendocrine tumors (pNETs), parathyroid tumors, or pituitary tumors. Using the PubMed database, we reviewed the literature on information regarding the proper diagnosis and treatment of MEN1-associated pNET. Many cases of MEN1-associated pNET are functioning pNETs. Gastrinomas and insulinomas tend to occur frequently in the duodenum and pancreas, respectively. In addition to diagnostic imaging, the selective arterial secretagogue injection test (SASI test) is useful for localizing functioning pNET. The standard treatment is surgical resection. However, in the case of a functioning pNET, the tumor should first be accurately located using the SASI test before an appropriate surgical method is selected. In cases of a MEN1-associated non-functioning pNET that exceeds 2 cm in diameter, the incidence of distant metastasis is significantly increased, and surgery is recommended. In cases of unresectable pNET, a somatostatin analog has been shown to demonstrate antitumor effects and is considered to be a promising treatment. In addition, molecular-targeted drugs have recently been found to be effective in phase III clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=84865427371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865427371&partnerID=8YFLogxK

U2 - 10.5009/gnl.2012.6.3.287

DO - 10.5009/gnl.2012.6.3.287

M3 - Review article

C2 - 22844555

AN - SCOPUS:84865427371

VL - 6

SP - 287

EP - 294

JO - Gut and Liver

JF - Gut and Liver

SN - 1976-2283

IS - 3

ER -